Kiniksa Pharmaceuticals, Ltd. (KNSA)

17.88 +0.27 (+1.53%) At close: 04:00PM EDT

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

https://www.kiniksa.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 297

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sanj K. Patel	CEO & Chairman of the Board	1.57M	N/A	1969
Mr. Eben Tessari	Senior VP & COO	733.29k	N/A	1982
Dr. John F. Paolini FACC, M.D., Ph.D.	Senior VP & Chief Medical Officer	855.79k	N/A	1965
Mr. Mark Ragosa C.F.A.	Senior VP & CFO	N/A	N/A	1974
Mr. Michael R. Megna CPA	Chief Accounting Officer & Group VP of Finance	N/A	N/A	1971
Ms. Mei Jang	Senior VP of Technical Operations	N/A	N/A	N/A
Rachel Frank	Associate Director of Investor Relations	N/A	N/A	N/A
Mr. Chad Morin	Senior VP & Chief Compliance Officer	N/A	N/A	N/A
Ms. Madelyn Demsky Zeylikman	SVP, General Counsel & Secretary	N/A	N/A	1974
Ms. Melissa Manno	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Corporate governance

Kiniksa Pharmaceuticals, Ltd.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.